Thermodynamic stability, unfolding kinetics, and aggregation of the N-terminal actin-binding domains of utrophin and dystrophin

Proteins: Structure, Function and Bioinformatics

Volumn 80, Issue 5, 2012, Pages 1377-1392

  Singh, Surinder M ^a   Molas, Justine F ^a   Kongari, Narsimulu ^a   Bandi, Swati ^a   Armstrong, Geoffrey S ^b   Winder, Steve J ^c   Mallela, Krishna M G ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Actin binding domain; Aggregation; Calponin homology domain; Disease; Dystrophin; Muscular dystrophy; Stability; Unfolding; Utrophin

Indexed keywords

DYSTROPHIN; UTROPHIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; GENE MUTATION; KINETICS; MOLECULAR MECHANICS; MOLECULAR STABILITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FOLDING; THERMODYNAMICS;

AMINO ACID SEQUENCE; BINDING SITES; CALCIUM-BINDING PROTEINS; CIRCULAR DICHROISM; DYSTROPHIN; HUMANS; KINETICS; MICROFILAMENT PROTEINS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN STABILITY; PROTEIN UNFOLDING; SEQUENCE ALIGNMENT; TEMPERATURE; THERMODYNAMICS; UTROPHIN;

ANIMALIA;

EID: 84862825847     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.24033     Document Type: Article

References (112)

1. Emery AEH. The muscular dystrophies. Lancet 2002; 359: 687-695.
2. Hoffman EP, Brown J, Robert H., Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-928.
3. Winder SJ. Dystrophin and utrophin: the missing links! FEBS Lett 1995; 369: 27-33.
4. Roberts RG. Protein family review: dystrophins and dystrobrevins. Gen Biol 2001; 2:reviews 3006.3001-3006.3007.
5. Ervasti JM. Dystrophin, its interactions with other proteins, and implications. Biochim Biophys Acta 2007; 1772: 108-117.
6. Roberts RG, Borrow M, Bentley DR. Point mutations in the dystrophin gene. Proc Natl Acad Sci USA 1992; 89: 2331-2335.
7. Roberts RG, Gardner RJ, Bobrow M. Searching for the 1 in 2, 400, 000: a review of dystrophin gene point mutations. Hum Mutat 1994; 4: 1-11.
8. Prior TW, Bartolo C, Pearl DK, Papp AC, Snyder PJ, Sedra MS, Burghes AHM, Mendell JR. Spectrum of small mutations in the dystrophin coding region. Am J Hum Genet 1995; 57: 22-33.
9. Sitnik R, Campiotto S, Vainzof M, Pavanello RC, Takata RI, Zatz M, Passos-Bueno MR. Novel point mutations in the dystrophin gene. Human Mutat 1997; 10: 217-222.
10. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: One gene, several proteins, multiple phenotypes. Lancet Neurol 2003; 2: 731-740.
11. Aaartsma-Rus A, van Deutekom JCT, Fokkema IF, van Ommen G-JB, Den Dennen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006; 34: 135-144.
12. Love DR, Hill DF, Dickson G, Spurr NK, Byth BC, Marsden RF, Walsh FS, Edwards YH, Davies KE. An autosomal transcript in skeletal muscle with homology to dystrophin. Nature 1989; 339: 55-58.
13. Khurana TS, Hoffman EP, Kunkel L. Identification of a chromosome 6-encoded dystrophin-related protein. J Biol Chem 1990; 265: 16717-16720.
14. Tinsley JM, Blake DJ, Roche A, Fairbrother U, Riss J, Byth BC, Knight AE, Kendrick-Jones J, Suthers GK, Love DR, Edwards YH, Davies KE. Primary structure of dystrophin-related protein. Nature 1992; 360: 591-593.
15. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002; 82: 291-329.
16. Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, Gillis J-M, Davies K. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nature Med 1998; 4: 1441-1444.
17. Rafael JA, Tinsley JM, Potter AC, Deconinck AE, Davies KE. Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat Genet 1998; 19: 79-82.
18. Chamberlain JS. Gene therapy of muscular dystrophy. Hum Mol Genet 2002; 11: 2355-2362.
19. van Deutekom JCT, van Ommen G-JB. Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet 2003; 4: 774-783.
20. Miura P, Jasmin BJ. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: How close are we? Trends Mol Med 2006; 12: 122-129.
21. Deol JR, Danialou G, Larochelle N, Bourget M, Moon J-S, Liu A-B, Gilbert R, Petrof BJ, Nalbantoglu J, Karpati G. Successful compensation for dystrophin deficiency by a helper-dependent adenovirus expressing full-length utrophin. Mol Ther 2007; 15: 1767-1774.
22. Odom GL, Gregorevic P, Allen JM, Finn E, Chamberlain JS. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol Ther 2008; 16: 1539-1545.
23. Sonnemann KJ, Heun-Johnson H, Turner AJ, Baltgalvis KA, Lowe DA, Ervasti JM. Functional substitution by TAT-utrophin in dystrophin-deficient mice. PLoS Med 2009; 6: e1000083.
24. Khurana TS, Watkins SC, Chafey P, Chelly J, Tome FMS, Fardeau M, Kaplan J-C, Kunkel LM. Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle. Neuromusc Disord 1991; 1: 185-194.
25. Love DR, Morris GE, Ellis JM, Fairbrother U, Marsden RF, Bloomfield JF, Edwards YH, Slater CP, Parry DJ, Davies KE. Tissue distribution of the dystrophin-related gene product and expression in the mdx and dy mouse. Proc Natl Acad Sci USA 1991; 88: 3243-3247.
26. Helliwell TR, Man NT, Morris GE, Davies KE. The dystrophin-related protein, utrophin, is expressed on the sarcolemma of regenerating human skeletal muscle fibers in dystrophies and inflammatory myopathies. Neuromusc Disord 1992; 2: 177-184.
27. Blake DJ, Tinsley JM, Davies KE. Utrophin: a structural and functional comparison to dystrophin. Brain Pathol 1996; 6: 37-47.
28. Ohlendieck K, Ervasti JM, Matsumura K, Kahl SD, Leveille CJ, Campbell KP. Dystrophin-related protein is localized to neuromuscular junctions of adult skeletal muscle. Neuron 1991; 7: 499-508.
29. Gramolini AO, Jasmin BJ. Duchenne muscular dystrophy and the neuromuscular junction: the utrophin link. BioEssays 1997; 19: 747-750.
30. Moores CA, Kendrick-Jones J. Biochemical characterization of the actin-binding properties of utrophin. Cell Motil Cytoskeleton 2000; 46: 116-128.
31. Pons F, Augier N, Léger JOC, Robert A, Tomé FMS, Fardeau M, Voit T, Nicholson LVB, Mornet D, Léger JJ. A homologue of dystrophin is expressed at the neuromuscular junctions of normal individuals and DMD patients, and of normal and mdx mice: immunological evidence. FEBS Lett 1991; 282: 161-165.
32. Matsumura K, Ervasti JM, Ohlendieck K, Kahl SD, Campbell KP. Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. Nature 1992; 360: 588-591.
33. Winder SJ, Hemmings L, Maciver SK, Bolton SJ, Tinsley JM, Davies KE, Critchley DR, Kendrick-Jones J. Utrophin actin binding domain: analysis of actin binding and cellular targeting. J Cell Sci 1995; 108: 63-71.
34. Rybakova IN, Patel JR, Davies KE, Yurchenco PD, Ervasti JM. Utrophin binds laterally along actin filaments and can couple costameric actin with sarcolemma when overexpressed in dystrophin-deficient muscle. Mol Biol Cell 2002; 13: 1512-1521.
35. Ishikawa-Sakurai M, Yoshida M, Imamura M, Davies KE, Ozawa E. ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to β-dystroglycan. Hum Mol Genet 2004; 13: 693-702.
36. Rybakova IN, Humston JL, Sonnemann KJ, Ervasti JM. Dystrophin and utrophin bind actin through distinct modes of contact. J Biol Chem 2006; 281: 9996-10001.
37. Prochniewicz E, Henderson D, Ervasti JM, Thomas DD. Dystrophin and utrophin have distinct effects on the structural dynamics of actin. Proc Natl Acad Sci USA 2009; 106: 7822-7827.
38. Squire S, Raymackers JM, Vandebrouck C, Potter A, Tinsley J, Fisher R, Gillis JM, Davies KE. Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. Hum Mol Genet 2002; 11: 3333-3344.
39. Ahmad A, Brinson M, Hodges BL, Chamberlain JS, Amalfitano A. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy. Hum Mol Genet 2000; 9: 2507-2515.
40. Keep NH, Winder SJ, Moores CA, Walke S, Norwood FLM, Kendrick-Jones J. Crystal structure of the actin-binding region of utrophin reveals a head-to-tail dimer. Structure 1999; 7: 1539-1546.
41. Norwood FL, Sutherland-Smith AJ, Keep NH, Kendrick-Jones J. The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy. Structure 2000; 8: 481-491.
42. Singh SM, Kongari N, Cabello-Villegas J, Mallela KMG. Missense mutations in dystrophin that trigger muscular dystrophy decrease protein stability and lead to cross-β aggregates. Proc Natl Acad Sci USA 2010; 107: 15069-15074.
43. Henderson DM, Lee A, Ervasti JM. Disease-causing missense mutations in actin binding domain 1 of dystrophin induce thermodynamic instability and protein aggregation. Proc Natl Acad Sci USA 2010; 107: 9632-9637.
44. Phelps SF, Hauser MA, Cole NM, Rafael JA, Hinkle RT, Faulkner JA, Chamberlain JS. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 1995; 4: 1251-1258.
45. Tinsley JM, Potter AC, Phelps SR, Fisher R, Trickett JI, Davies KE. Amelioration of the dystrophin phenotype of mdx mice using a truncated utrophin transgene. Nature 1996: 349-353.
46. Deconinck N, Tinsley J, Backer FD, Fisher R, Kahn D, Phelps S, Davies K, Gillis J-M. Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice. Nat Med 1997; 3: 1216-1221.
47. Gilbert R, Nalbantoglu J, Petrof BJ, Ebihara S, Guibinga GH, Tinsley JM, Kamen A, Massie B, Davies KE, Karpati G. Adenovirus-mediated utrophin gene transfer mitigates the dystrophin phenotype of mdx mouse muscles. Hum Gene Ther 1999; 10: 1299-1310.
48. Wakefield PM, Tinsley JM, Wood MJA, Gilbert R, Karpati G, Davies KE. Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene. Gene Therapy 2000; 7: 201-204.
49. Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 2000; 97: 13714-13719.
50. Gregorevic P, Allen JM, Minami E, Blankenship MJ, Haraguchi M, Meuse L, Finn E, Adams ME, Froehner SC, Murry CE, Chamberlain JS. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006; 12: 787-789.
51. Scott JM, Li S, harper SQ. Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. Neuromuscular Disord 2002; 12: s23-s29.
52. Gregorevic P, Chamberlain JS. Gene therapy for muscular dystrophy-a review of promising progress. Expert Opin Biol Ther 2003; 3: 803-814.
53. Foster K, Foster H, Dickson JG. Gene therapy progress and prospects: Duchenne muscular dystrophy. Gene Ther 2006; 13: 1677-1685.
54. Muir LA, Chamberlain JS. Emerging strategies for cell and gene therapy of the muscular dystrophies. Expert Rev Mol Med 2009; 11: e18.
55. Fairclough RJ, Bareja A, Davies KE. Progress in therapy for Duchenne muscular dystrophy. Exp Physiol 2011; 96: 1101-1113.
56. Henderson DM, Belanto JJ, Li B, Heun-Johnson H, Ervasti JM. Internal deletion compromises the stability of dystrophin. Hum Mol Genet 2011; 20: 2955-2963.
57. Le Rumeur E, Winder SJ, Hubert J-F. Dystrophin: more than just the sum of its parts. Biochim Biophys Acta 2010; 1804: 1713-1722.
58. Orlova A, Rybakova IN, Prochniewicz E, Thomas DD, Ervasti JM, Egelman EH. Binding of dystrophin's tandem calponin homology domain to F-actin is modulated by actin's structure. Biophys J 2001; 80: 1926.
59. Gimona M, Djinovic-Carugo K, Kranewitter WJ, Winder SJ. Functional plasticity of CH domains. FEBS Lett 2002; 513: 98-106.
60. Galkin VE, Orlova A, VanLoock MS, Egelman EH. Do the utrophin tandem calponin homology domains bind F-actin in a compact or extended conformation? J Mol Biol 2003; 331: 967-972.
61. Lehman W, Craig R, Kendrick-Jones J, Sutherland-Smith A. An open or closed case for the conformation of calponin homology domains on F-actin? J Muscle Res Cell Motility 2004; 25: 351-358.
62. Galkin VE, Orlova A, Salmazo A, Djinovic-Carugo K, Egelman EH. Opening of tandem calponin homology domains regulated their affinity for F-actin. Nat Struct Mol Biol 2010; 17: 614-616.
63. Lin AY, Prochniewicz E, James ZM, Svensson B, Thomas DD. Large-scale opening of utrophin's tandem calponin homology (CH) domains upon actin binding by an induced-fit mechanism. Proc Natl Acad Sci USA 2011; 108: 12729-12733.
64. Sutherland-Smith AJ, Moores CA, Norwood FLM, Hatch V, Craig R, Kendrick-Jones J, Lehman W. An atomic model for actin binding by the CH domains and spectrin-repeat modules of utrophin and dystrophin. J Mol Biol 2003; 329: 15-33.
65. Greenfield NJ. Using circular dichroism spectra to estimate protein secondary structure. Nat Protocols 2006; 6: 2876-2890.
66. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 1995; 6: 277-293.
67. Santoro MM, Bolen DW. Unfolding free energy changes determined by the linear extrapolation method. 1. Unfolding of phenylmethanesulfonyl alpha-chymotrypsin using different denaturants. Biochemistry 1988; 27: 8063-8068.
68. Santoro MM, Bolen DW. A test of the linear extrapolation of unfolding free energy changes over an extended denaturant concentration range. Biochemistry 1992; 31: 4901-4907.
69. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, Thompson JD. Multiple sequence alignment with the Clustal series of programs. Nucl Acids Res 2003; 31: 3497-3500.
70. Shatsky M, Nussinov R, Wolfson HJ. A method for simultaneous alignment of multiple protein structures. Protein Struct Funct Bioinform 2004; 56: 143-156.
71. Lakowicz JR. Principles of fluorescence spectroscopy. New York: Springer Science; 2006.
72. 15N NMR relaxation. Prog NMR Spectroscopy 1997; 31: 63-105.
73. Myers JK, Pace CN, Scholtz JM. Denaturant m values and heat capacity changes: relation to changes in accessible surface areas of protein unfolding. Protein Sci 1995; 4: 2138-2148.
74. Kahana E, Flood G, Gratzer WB. Physical properties of dystrophin rod domain. Cell Motil Cytoskeleton 1997; 36: 246-252.
75. Ruszczak C, Mirza A, Menhart N. Differential stabilities of alternative exon-skipped rod motifs of dystrophin. Biochim Biophys Acta 2009; 1794: 921-928.
76. Legardinier S, Legrand B, Raguénès-Nicol C, Bondon A, Hardy S, Tascon C, Rumeur EL, Hubert J-F. A two-amino acid mutation encountered in Duchenne muscular dystrophy decreases stability of the rod domain 23 (R23) spectrin-like repeat of dystrophin. J Biol Chem 2009; 284: 8822-8832.
77. Krishna MMG, Englander SW. A unified mechanism for protein folding: predetermined pathways with optional errors. Protein Sci 2007; 16: 449-464.
78. Mirza A, Sagathevan M, Sahni N, Choi L, Menhart N. A biophysical map of the dystrophin rod. Biochim Biophys Acta 2010; 1804: 1796-1809.
79. Park C, Marqusee S. Probing the high energy states in proteins by proteolysis. J Mol Biol 2004; 343: 1467-1476.
80. Singh SM, Cabello-Villegas J, Hutchings RL, Mallela KMG. Role of partial protein unfolding in alcohol-induced protein aggregation. Protein Struct Funct Bioinform 2010; 78: 2625-2637.
81. Belli M, Ramazzotti M, Chiti F. Prediction of amyloid aggregation in vivo. EMBO Reports 2011; 12: 657-663.
82. Levine-III H. Thioflavine T interaction with synthetic Alzheimer's disease {beta}-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci 1993; 2: 404-410.
83. Klunk WE, Pettegrew JW, Abraham DJ. Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleatedsheet conformation. J Histochem Cytochem 1989; 37: 1273-1281.
84. Rafael JA, Townsend ER, Squire SE, Potter AC, Chamberlain JS, Davies KE. Dystrophin and utrophin influence fiber type composition and post-synaptic membrane structure. Hum Mol Genet 2000; 9: 1357-1367.
85. Pastoret C, Sebille A. Mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci 1995; 129: 97-105.
86. Tanabe Y, Esaki K, Nomura T. Skeletal muscle pathology in X chromosome-linked muscular dystrophy (mdx) mouse. Acta Neuropathol 1986; 69: 91-95.
87. Karpati G, Carpenter S, Morris GE, Davies KE, Guerin C, Holland P. Localization and quantitation of the chromosome 6-encoded dystrophin-related protein in normal and pathological human muscle. J Neuropathol Exp Neurol 1993; 52: 119-128.
88. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, Watt DJ, Dickson JG, Tinsley JM, Davies KE. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997; 90: 717-727.
89. Grady RM, Teng HB, Nichol MC, Cunningham JC, Wilkinson RS, Sanes JR. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 1997; 90: 729-738.
90. Odom GL, Gregorevic P, Chamberlain JS. Viral-mediated gene therapy for the muscular dystrophies: successes, limitations, and recent advances. Biochim Biophys Acta 2007; 1772: 243-262.
91. Ebihara S, Guibinga G-H, Gilbert R, Nalbantoglu J, Massie B, Karpati G, Petrof BJ. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice. Physiol Genomics 2000; 3: 133-144.
92. Parsell DA, Sauer RT. The structural stability of a protein is an important determinant of its proteolytic susceptibility in Escherichia coli. J Biol Chem 1989; 264: 7590-7595.
93. Wang L, Kallenbach NR. Proteolysis as a measure of the free energy difference between cytochrome c and its derivatives. Protein Sci 1998; 7: 2460-2464.
94. Kim M-S, Song J, Park C. Determining protein stability in cell lysates by pulse proteolysis and Western blotting. Protein Sci 2009; 18: 1051-1059.
95. Ruschak AM, Religa TL, Breuer S, Witt S, Kay LE. The proteasome antechamber maintains substrates in the unfolded state. Nature 2010; 467: 868-871.
96. Cotton P, Poussard S, Mornet D, Brustis JJ, Mohammadpour M, Leger J, Ducastaing A. In vitro digestion of dystrophin by calcium-dependent proteases, calpains I and II. Biochimie 1992; 74: 565-570.
97. Courdier-Fruh I, Briguet A. Utrophin is a calpain substrate in muscle cells. Muscle Nerve 2006; 33: 753-759.
98. Badorff C, Lee G-H, Lamphear BJ, Martone ME, Campbell KP, Rhoads RE, Knowlton KU. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999; 5: 320-326.
99. Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharmaceut Res 2003; 20: 1325-1336.
100. Mayer S, Rüdiger S, Ang HC, Joerger AC, Fersht AR. Correlation of levels of folded recombinant p53 in Escherichia coli with thermodynamic stability in vitro. J Mol Biol 2007; 372: 268-276.
101. Espargaró A, Castillo V, de Groot NS, Ventura S. The in vivo and in vitro aggregation properties of globular proteins correlate with their conformational stability: the SH3 case. J Mol Biol 2008; 378: 1116-1131.
102. Prior TW, Papp AC, Snyder PJ, Burghes AHM, Bartolo C, Sedra MS, Western LM, Mendell JR. A missense mutation in the dystrophin gene in a Duchenne muscular dystrophy patient. Nat Genet 1993; 4: 357-360.
103. Hamed SA, Sutherland-Smith AJ, Gorospe JRM, Kendrick-Jones J, Hoffman EP. DNA sequence analysis for structure/function and mutation studies in Becker muscular dystrophy. Clin Genet 2005; 68: 69-79.
104. Fisher R, Tinsley JM, Phelps SR, Squire SE, Townsend ER, Martin JE, Davies KE. Non-toxic ubiquitous over-expression of utrophin in the mdx mouse. Neuromusc Disorder 2001; 11: 713-721.
105. Pearce M, Blake DJ, Tinsley JM, Byth BC, Campbell L, Monaco AP, Davies KE. The utrophin and dystrophin genes share similarities in genomic structure. Hum Mol Genet 1993; 2: 1765-1772.
106. Ito H, Yoshimura T, Satoh A, Takino H, Tsujihata M, Nagataki S. Immunohistochemical study of utrophin and dystrophin at the motor end-plate in myasthenia gravis. Acta Neuropathol 1996; 92: 14-18.
107. Sieb JP, Kraner S, Rauch M, Steinlein OK. Immature end-plates and utrophin deficiency in congenital myasthemic syndrome caused by ε-AChR subunit truncating mutations. Hum Genet 2000; 107: 160-164.
108. Barghorn A, Speel EJM, Farspour B, Saremaslani P, Schmid S, Perren A, Roth J, Heitz PU, Komminoth P. Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am J Pathol 2001; 158: 1903-1911.
109. Nagarajan R, Le N, Mahoney H, Araki T, Milbrandt J. Deciphering peripheral nerve myelination by using Schwann cell expression profiling. Proc Natl Acad Sci USA 2002; 99: 8998-9003.
110. Knuesel I, Riban V, Zuellig RA, Schaub MC, Grady RM, Sanes JR, Fritschy J-M. Increased vulnerability to kainate-induced seizures in utrophin-knockout mice. Eur J Neurosci 2002; 15: 1474-1484.
111. Li Y, Huang J, Zhao Y-L, He J, Wang W, Davies KE, Nosé V, Xiao S. UTRN on chromosome 6q24 is mutated in multiple tumors. Oncogene 2007; 26: 6220-6228.
112. Mallela K, Singh S, Molas J, Cabello-Villegas J, Kongari N. Protein stability, folding, and aggregation of the N-terminal actin binding domains of dystrophin and utrophin. Protein Sci 2010; 19(S1): 180.